Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Get Free Report) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.40 and traded as low as $2.26. Creative Medical Technology shares last traded at $2.29, with a volume of 21,929 shares traded.
Creative Medical Technology Price Performance
The firm has a 50-day moving average of $3.17 and a 200 day moving average of $3.38. The stock has a market capitalization of $4.00 million, a price-to-earnings ratio of -0.60 and a beta of 1.76.
Hedge Funds Weigh In On Creative Medical Technology
A hedge fund recently raised its stake in Creative Medical Technology stock. Aaron Wealth Advisors LLC grew its position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) by 19.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,570 shares of the company’s stock after acquiring an additional 3,170 shares during the period. Aaron Wealth Advisors LLC owned about 1.45% of Creative Medical Technology worth $75,000 at the end of the most recent quarter. Institutional investors own 1.42% of the company’s stock.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.
Read More
- Five stocks we like better than Creative Medical Technology
- Investing In Automotive Stocks
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- What Are the U.K. Market Holidays? How to Invest and Trade
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- How to Capture the Benefits of Dividend Increases
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.